Upadacitinib Demonstrates Efficacy for Non-Segmental Vitiligo in Phase 3 Trials

Two phase 3 clinical trials, Viti-Up-1 and Viti-Up-2, have shown that a 15 mg daily dose of upadacitinib significantly improved repigmentation in adults and adolescents with non-segmental vitiligo. The studies reported consistent safety profiles without new concerns. These findings suggest a potential new treatment option for a condition that can significantly impact quality of life.